1.Anstee, Q. M.,Reeves, H. L., Kotsiliti, E., Govaere, O., and Heikenwalder, M. (2019). FromNASH to HCC: Current Concepts and Future Challenges. Nat. Rev. Gastroenterol.Hepatol. 16 (7), 411–428. doi:10.1038/s41575-019-0145-7

2.Behary, J., Amorim,N., Jiang, X. T., Raposo, A., Gong, L., McGovern, E., et al. (2021). GutMicrobiota Impact on the Peripheral Immune Response in Nonalcoholic Fatty LiverDisease Related Hepatocellular Carcinoma. Nat. Commun.12 (1), 187.doi:10.1038/s41467-020-20422-7

3.Bose, S., Le, A.,and Le, A. (2021). Glucose Metabolism in Cancer. Adv. Exp. Med.Biol.1063, 3–12.doi:10.1007/978-3-030-65768-0_110.1007/978-3-319-77736-8_1

4.Broadfifield, L.A., Duarte, J. A. G., Schmieder, R., Broekaert, D., Veys, K., Planque, M., etal. (2021). Fat Induces Glucose Metabolism in Nontransformed Liver

Cells and PromotesLiver Tumorigenesis. Cancer Res. 81 (8), 1988–2001. doi:10.1158/0008-5472.CAN-20-1954

5.Bruix, J., Qin, S.,Merle, P., Granito, A., Huang, Y. H., Bodoky, G., et al. (2017). Regorafenibfor Patients with Hepatocellular Carcinoma Who Progressed on SorafenibTreatment (RESORCE): a Randomised, Double-Blind,PlaceboControlled, Phase 3Trial. Lancet 389 (10064), 56–66. doi:10.1016/S0140-6736(16)32453-9

6.Buoso, E., Kenda,M., Masi, M., Linciano, P., Galbiati, V., Racchi, M., et al.(2021).Effects ofBisphenols on RACK1 Expression and Their Immunological Implications in THP-1Cells. Front. Pharmacol.12, 743991. doi:10.3389/

fphar.2021.743991

7.Cai, X., Bao, L.,Wang, N., Ren, J., Chen, Q., Xu, M., et al. (2016). Dietary Nucleotides Protectagainst Alcoholic Liver Injury by Attenuating Inflflammation and Regulating GutMicrobiota in Rats. Food Funct. 7,2898–2908. doi:10.1039/c5fo01580d

8.Cai, X., Bao, L.,Wang, N., Xu, M., Mao, R., and Li, Y. (2016). Dietary NucleotidesSupplementation and Liver Injury in Alcohol-Treated Rats: A Metabolomics

Investigation.Molecules 21 (4), 435. doi:10.3390/

molecules21040435

9.Cao, F., Yang, Y.,Si, T., Luo, J., Zeng, H., Zhang, Z., et al. (2021). The Effificacy of TACECombined with Lenvatinib Plus Sintilimab in Unresectable HepatocellularCarcinoma: A Multicenter Retrospective Study. Front. Oncol. 11, 783480.doi:10.3389/fonc.2021.783480

10.Chen, J., Hu, X.,Li, Q., Dai, W., Cheng, X., Huang, W., et al. (2020). Effectiveness and Safetyof Toripalimab, Camrelizumab, and Sintilimab in a Real-World Cohort ofHepatitis B Virus Associated Hepatocellular Carcinoma Patients. Ann. Transl.Med. 8 (18), 1187.doi:10.21037/atm-20-6063

11.Chen, W., Zheng,R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., et al. (2016). CancerStatistics in China, 2015. CA Cancer J. Clin. 66 (2), 115–132.doi:10.3322/caac.

21338

12.Choi, J., Jo, C.,and Lim, Y. S. (2021). Tenofovir Versus Entecavir on Recurrence of Hepatitis BVirus-Related Hepatocellular Carcinoma After Surgical Resection.

Hepatology 73 (2),661–673. doi:10.1002/hep.31289

13.Ding, X., Sun, W.,and Chen, J. (2018). IL-2 Augments the Sorafenib-Induced Apoptosis in LiverCancer by Promoting Mitochondrial Fission and Activating the JNK/TAZ Pathway.Cancer Cell. Int. 18,176.doi:10.1186/s12935-018-

0671-3

14.Donisi, C.,Puzzoni, M., Ziranu, P., Lai, E., Mariani, S., Saba, G., et al. (2020).

Immune CheckpointInhibitors in the Treatment of HCC. Front. Oncol. 10, 601240.doi:10.3389/fonc.2020.601240

15.Du, Y., Shi, X.,Ma, W., Wen, P., Yu, P., Wang, X., et al. (2021). Phthalates Promote theInvasion ofHepatocellular Carcinoma Cells by Enhancing theInteraction betweenPregnane X Receptor and E26 Transformation Specifific Sequence 1. Pharmacol.Res. 169, 105648. doi:10.1016/j.phrs.2021.105648

16.Feng, F., Jiang,Q., Cao, S., Cao, Y., Li, R., Shen, L., et al. (2018). Pregnane X ReceptorMediates Sorafenib Resistance in Advanced Hepatocellular Carcinoma. Biochim.Biophys. Acta Gen. Subj. 1862 (4), 1017–1030. doi:10.

1016/j.bbagen.2018.01.011

17.Feng, F., Jiang,Q., Jia, H., Sun, H., Chai, Y., Li, X., et al. (2018). Which Is the BestCombination of TACE and Sorafenib for Advanced Hepatocellular CarcinomaTreatment? A Systematic Review and Network Meta-Analysis. Pharmacol. Res. 135,89–101. doi:10.1016/j.phrs.2018.06.021

18.Feng, F., Li, X.,Li, R., and Li, B. (2019). The Multiple-Kinase Inhibitor Lenvatinib Inhibitsthe Proliferation of Acute Myeloid Leukemia Cells. Anim. Model. Exp. Med. 2(3), 178–184. doi:10.1002/ame2.12076

19.Feng, Y. Q., Li,B. A., Feng, F., Chen, Y. S., Ren, Y. X., Zhang, H., et al. (2020). Novel mTORInhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to

Molecular TargetingAgents. Onco Targets Ther. 2713, 7165–7176. doi:10.2147/ OTT.S244474

19.Fessas, P.,Possamai, L. A., Clark, J., Daniels, E., Gudd, C., Mullish, B. H., et al.(2020). Immunotoxicity from Checkpoint Inhibitor Therapy: Clinical Features

and UnderlyingMechanisms. Immunology 159 (2), 167–177. doi:10.1111/imm. 13141

20.Finn, R. S., Ryoo,B. Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., et al. (2020).Pembrolizumab As Second-Line Therapy in Patients with Advanced HepatocellularCarcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J. Clin.Oncol. 38 (3),193–202.doi:10.1200/JCO.19.01307

21.Forner, A., Reig,M., and Bruix, J. (2018). Hepatocellular Carcinoma. Lancet 391 (10127),1301–1314. doi:10.1016/S0140-6736(18)30010-2

22.Fujii, H., andKawada, N.Japan Study Group Of Naflfld Jsg-Naflfld (2020). The Role of InsulinResistance and Diabetes in Nonalcoholic Fatty Liver Disease. Int. J. Mol.

Sci. 21 (11), 3863.doi:10.3390/ijms21113863

23.Giraud, J.,Chalopin, D., Blanc, J. F., and Saleh, M. (2021). Hepatocellular CarcinomaImmune Landscape and the Potential of Immunotherapies. Front. Immunol. 12,655697. doi:10.3389/fifimmu.2021.655697

24.Gordan, J. D.,Kennedy, E. B., Abou-Alfa, G. K., Beg, M. S., Brower, S. T., Gade, T. P., etal. (2020). Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.J. Clin. Oncol. 38 (36), JCO2002672–4345. doi:10.1200/JCO. 20.02672

25.Guan, F., Ding,R., Zhang, Q., Chen, W., Li, F., Long, L., et al. (2017). WX-132-18B, a NovelMicrotubule Inhibitor, Exhibits Promising Anti-tumor Effects. Oncotarget 8(42), 71782–71796. doi:10.18632/oncotarget.17710

26.Guan, Q., Ding, X.W., Zhong, L. Y., Zhu, C., Nie, P., and Song, L. H. (2021). BenefificialEffects of Lactobacillus-Fermented Black Barley on High Fat Diet

Induced Fatty Liverin Rats. Food Funct. 12 (14),6526–6539. doi:10.1039/d1fo00290b

27.Han, Y., Liu, D.,and Li, L. (2020). PD-1/PD-L1 Pathway: Current Researches in Cancer. Am. J.Cancer Res. 10 (3), 727–742.

28.He, X., Sun, H.,Jiang, Q., Chai, Y., Li, X., Wang, Z., et al. (2021). Hsa-miR-4277 Deceleratesthe Metabolism or Clearance of Sorafenib in HCC Cells and Enhances theSensitivity of HCC Cells to Sorafenib by Targeting Cyp3a4.

Front. Oncol. 11,735447. doi:10.3389/fonc.2021.735447

29.He, Y., Luo, Y.,Huang, L., Zhang, D., Wang, X., Ji, J., et al. (2021). New Frontiers

against SorafenibResistance in Renal Cell Carcinoma: From Molecular Mechanisms to PredictiveBiomarkers. Pharmacol. Res. 170, 105732. doi:10. 1016/j.phrs.2021.105732

30.Hu, H. J., Wang,X. H., Liu, Y., Zhang, T. Q., Chen, Z. R., Zhang, C., et al. (2021). HydrogenSulfifide

AmelioratesAngiotensin II-Induced Atrial Fibrosis

Progression to AtrialFibrillation through Inhibition of the Warburg Effect and Endoplasmic ReticulumStress. Front. Pharmacol. 12, 690371. doi:10.3389/ fphar.2021.690371

31.Hu, Y., Qin, T.,Li, S., Zhang, T., and Xue, J. (2020). Effificacy and Safety of SBRT Combinedwith Camrelizumab and Apatinib in HCC Patients with PVTT: Study Protocol of aRandomized Controlled Trial. Front. Oncol. 10, 1589.

doi:10.3389/fonc.2020.01589

32.Huang, D. Q.,El-Serag, H. B., and Loomba, R. (2021). Global Epidemiology of NAFLD-RelatedHCC: Trends, Predictions, Risk Factors and Prevention. Nat. Rev. Gastroenterol.Hepatol. 18 (4), 223–238.doi:10.1038/s41575-020-00381-6

33.Javan, H.,Dayyani, F., and Abi-Jaoudeh, N. (2020). Therapy in Advanced HepatocellularCarcinoma. Semin. Interv. Radiol. 37 (5), 466–474. doi:10.1055/s-0040-1719187

34.Jia, H., Liu, M.,Wang, X., Jiang, Q., Wang, S., Santhanam, R. K., et al. (2021). CimigenosideFunctions as a Novel γ-secretase Inhibitor and Inhibits the

Proliferation orMetastasis of Human Breast Cancer Cells by γ-secretase/ Notch axis. Pharmacol.Res. 169, 105686. doi:10.1016/j.phrs.2021.105686

35.Jia, H., Wang, Z.,Zhang, J., and Feng, F. (2021). γ-Secretase Inhibitors for Breast Cancer andHepatocellular Carcinoma: From Mechanism to Treatment. Life Sci. 268, 119007.doi:10.1016/j.lfs.2020.119007

36.Jia, H., Yang, Q.,Wang, T., Cao, Y., Jiang, Q. Y., Ma, H. D., et al. (2016). Rhamnetin InducesSensitization of Hepatocellular Carcinoma Cells to a Small Molecular

Kinase Inhibitor orChemotherapeutic Agents. Biochim. Biophys. Acta 1860 (7), 1417–1430.doi:10.1016/j.bbagen.2016.04.007

37.Jiang, Q., Ma, Y.,Han, J., Chu, J., Ma, X., Shen, L., et al. (2021). MDM2 Binding Protein Inducesthe Resistance of Hepatocellular Carcinoma Cells to Molecular

Targeting Agents viaEnhancing the Transcription Factor Activity of the Pregnane X Receptor. Front.Oncol. 11, 715193. doi:10.3389/fonc.2021.715193

38.Kelley, R. K.,Sangro, B., Harris, W., Ikeda, M., Okusaka, T., Kang, Y. K., et al. (2021).Safety, Effificacy, and Pharmacodynamics of Tremelimumab Plus

Durvalumab forPatients with Unresectable Hepatocellular Carcinoma: Randomized Expansion of aPhase I/II Study. J. Clin. Oncol. 39 (27), 2991–3001.doi:10.1200/JCO.20.03555

39.Kim, D. W.,Talati, C., and Kim, R. (2017).Hepatocellular Carcinoma (HCC): beyondSorafenib-Chemotherapy. J. Gastrointest. Oncol. 8 (2), 256–265. doi:10.21037/jgo.2016.09.07

40.Kudo, M., Finn, R.S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., et al. (2018). Lenvatinibversus Sorafenib in First-Line Treatment of Patients with

UnresectableHepatocellular Carcinoma: a Randomised Phase 3 Noninferiority Trial. Lancet 391(10126), 1163–1173. doi:10.1016/S0140- 6736(18)30207-1

41.Li, B., Feng, F.,Jia, H., Jiang, Q., Cao, S., Wei, L., et al. (2021). Rhamnetin Decelerates theElimination and Enhances the Antitumor Effect of the Molecular-Targeting AgentSorafenib in Hepatocellular Carcinoma Cells via

the miR-148a/PXRaxis. Food Funct. 12 (6), 2404–2417. doi:10.1039/d0fo02270e

42.Li, F., Long, L.,Xiao, J., Wang, C., Li, W., Li, S., et al. (2017). A Novel HydroxyphenylHydrazone Derivate YCL0426 Inhibits Cancer Cell Proliferation throughSequestering Iron. Anticancer Drugs 28 (10), 1131–1140.doi:10.1097/CAD.0000000000000557

43.Li, F., Wei, A.,Bu, L., Long, L., Chen, W., Wang, C., et al. (2018). Procaspase-3-activatingCompound 1 Stabilizes Hypoxia-Inducible Factor 1α and Induces

DNA Damage bySequestering Ferrous Iron. Cell. Death Dis. 9 (10),1025.doi:10.1038/s41419-018-1038-3

44.Li, L., Kang, L.,Zhao, W., Feng, Y., Liu, W., Wang, T., et al. (2017). miR-30a-5p SuppressesBreast Tumor Growth and Metastasis through Inhibition of LDHAMediated WarburgEffect. Cancer Lett. 400, 89–98.doi:10.1016/j.canlet.2017.04.034

45.Li, L., Liang, Y.,Kang, L., Liu, Y., Gao, S., Chen, S., et al. (2018). Transcriptional Regulationof the Warburg Effect in Cancer by SIX1. Cancer Cell. 33 (3), 368.doi:10.1016/j.ccell.2018.01.010

46.Liu, J., Yang, C.,Huang, X.-M., Lv, P.-P., Yang, Y.-K., Zhao, J.-N., et al. (2021). Knockdown ofFBI-1 Inhibits the Warburg Effect and Enhances the Sensitivity

of HepatocellularCarcinoma Cells to Molecular Targeted Agents via miR-3692/HIF-1α. Front. Oncol.11, 796839. doi:10.3389/fonc.2021.796839

47.Liu, X., Lu, Y.,and Qin, S. (2021). Atezolizumab and Bevacizumab for Hepatocellular Carcinoma:Mechanism, Pharmacokinetics and Future Treatment Strategies.

Future Oncol. 17(17), 2243–2256.doi:10.2217/fon-2020-1290

48.Llovet, J. M.,Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., etal. (2022). Immunotherapies for Hepatocellular Carcinoma. Nat. Rev.Clin.Oncol.19 (3),151–172.doi: 10.1038/s41571-021-00573-2

49.Llovet, J. M.,Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., et al.(2021). Hepatocellular Carcinoma. Nat. Rev. Dis. Prim. 7 (1), 6. doi:10.1038/s41572-020-00240-3

50.Loong, J. H.,Wong, T. L., Tong, M., Sharma, R., Zhou, L., Ng, K. Y., et al. (2021). GlucoseDeprivation-Induced Aberrant FUT1-Mediated Fucosylation Drives Cancer Stemnessin Hepatocellular Carcinoma. J. Clin. Invest. 131 (11), e143377.doi:10.1172/JCI143377

51.Lu, X., Ce, Q.,Jin, L., Zheng, J., Sun, M., Tang, X., et al. (2021). Deoiled Sunflflower SeedsAmeliorate Depression by Promoting the Production of Monoamine

Neurotransmitters andInhibiting Oxidative Stress. Food Funct. 12 (2), 573–586.doi:10.1039/d0fo01978j

52.Ma, D., Jia, H.,Qin, M., Dai, W., Wang, T., Liang, E., et al. (2015). MiR-122 InducesRadiosensitization in Non-Small Cell Lung Cancer Cell Line. Int. J. Mol. Sci.16

(9), 22137–22150.doi:10.3390/ijms160922137

53.Ma, Y., Chai, N.,Jiang, Q., Chang, Z., Chai, Y., Li, X., et al. (2020). DNA MethyltransferaseMediates the Hypermethylation of the microRNA 34a Promoter and Enhances theResistance of Patient-Derived Pancreatic

Cancer Cells toMolecular Targeting Agents. Pharmacol. Res. 160, 105071.doi:10.1016/j.phrs.2020.105071

54.McGlynn, K. A.,Petrick, J. L., and El-Serag, H. B. (2021). Epidemiology of HepatocellularCarcinoma. Hepatology 73, 4–13. doi:10.1002/hep.31288

55.Mittal, L., Tonk,R. K., Awasthi, A., and Asthana, S. (2021). Targeting CrypticOrthosteric Siteof PD-L1 for Inhibitor Identifification Using Structure-Guided

Approach. ArchivesBiochem. Biophysics 713, 109059. doi:10.1016/j.abb.2021.109059

56.Mohr, R., Özdirik,B., Lambrecht, J., Demir, M., Eschrich, J., Geisler, L., et al. (2021). FromLiver Cirrhosis to Cancer: The Role of Micro-RNAs in

Hepatocarcinogenesis.Int. J. Mol. Sci. 22 (3), 1492. doi:10.3390/ijms22031492

57.Pinter, M.,Scheiner, B., and Peck-Radosavljevic, M. (2021). Immunotherapy for AdvancedHepatocellular Carcinoma: a Focus on Special Subgroups. Gut 70 (1),

204–214.doi:10.1136/gutjnl-2020-321702

58.PolarisObservatory Collaborators (2018). Global Prevalence, Treatment, and Prevention ofHepatitis B Virus Infection in 2016: a Modelling Study. Lancet Gastroenterol.Hepatol. 3 (6), 383–403.doi:10.1016/S2468-1253(18)

30056-6

59.PolarisObservatory HCV Collaborators (2022). Global Change in Hepatitis C VirusPrevalence and Cascade of Care between 2015 and 2020: a Modelling Study. LancetGastroenterol. Hepatol. 7 (5),396–415.doi:10.1016/S2468- 1253(21)00472-6

60.Powell, E. E.,Wong, V. W., and Rinella, M. (2021). Non-alcoholic Fatty Liver Disease. Lancet397 (10290), 2212–2224. doi:10.1016/S0140-6736(20) 32511-3

61.Raza, S., Rajak,S., Upadhyay, A., Tewari, A., and Anthony Sinha, R. (2021). Current TreatmentParadigms and Emerging Therapies for NAFLD/NASH. Front. Biosci. (Landmark Ed.26 (2), 206–237. doi:10.2741/4892

62.Roskoski, R., Jr.(2019). Properties of FDA-Approved Small Molecule Protein Kinase Inhibitors.Pharmacol. Res. 144, 19–50. doi:10.1016/j.phrs.2019.03.006

63.Roskoski, R., Jr.(2020). Properties of FDA-Approved Small Molecule Protein Kinase Inhibitors: A2020 Update. Pharmacol. Res. 152, 104609. doi:10.1016/j.phrs.2019.104609

64.Roskoski, R., Jr.(2021). Properties of FDA-Approved Small Molecule Protein Kinase Inhibitors: A2021 Update. Pharmacol. Res. 165, 105463. doi:10.1016/j.phrs.2021.105463

65.Roskoski, R., Jr.(2022). Properties of FDA-Approved Small Molecule Protein Kinase Inhibitors: A2022 Update. Pharmacol. Res. 175, 106037. doi:10.1016/j.phrs.2021.106037

66.Santos Ferreira,R. D., Dos Santos, C., Maranhão Mendonça, L. A. B., Espinola Carvalho, C. M.,and Franco, O. L. (2021). Immunonutrition Effects on Coping with COVID-19. FoodFunct. 12 (17), 7637–7650. doi:10.1039/

d1fo01278a

67.Shanti, A.,Hallfors, N., Petroianu, G. A., Planelles, L., and Stefanini, C. (2021). LymphNodes-On-Chip: Promising Immune Platforms for Pharmacological

and ToxicologicalApplications. Front. Pharmacol. 12, 711307. doi:10.3389/ fphar.2021.711307

68.Shao, Z., Li, Y.,Dai, W., Jia, H., Zhang, Y., Jiang, Q., et al. (2018). ETS-1 Induces

Sorafenib-Resistancein Hepatocellular Carcinoma Cells via Regulating Transcription Factor Activityof PXR. Pharmacol. Res. 135, 188–200. doi:10.1016/j.phrs.2018.08.003

69.Shi, D., An, X.,Bai, Q., Bing, Z., Zhou, S., Liu, H., et al. (2019). Computational Insight Intothe Small Molecule Intervening PD-L1 Dimerization and the

PotentialStructure-Activity Relationship. Front. Chem. 7, 764. doi:10.3389/fchem.2019.00764

70.Sun, H., Feng, F.,Xie, H., Li, X., Jiang, Q., Chai, Y., et al. (2019). Quantitative Examinationof the Inhibitory Activation of Molecular Targeting Agents in

HepatocellularCarcinoma Patient-Derived Cell Invasion via a Novel In Vivo Tumor Model. Anim.Model. Exp. Med. 2 (4), 259–268. doi:10.1002/ame2. 12085

71.Sung, H., Ferlay,J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021).Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and

Mortality Worldwidefor 36 Cancers in 185 Countries. CA A Cancer J. Clin. 71 (3), 209–249.doi:10.3322/caac.21660

72.Vaupel, P., andMulthoff, G. (2021). The Warburg Effect: Historical Dogma Versus CurrentRationale. Adv. Exp. Med. Biol. 1269, 169–177. doi:10.1007/978-3-030-48238-1_27

73.Wang, F. S., Fan,J. G., Zhang, Z., Gao, B., and Wang, H. Y. (2014). The Global Burden of LiverDisease: the Major Impact of China. Hepatology 60 (6), 2099–2108.doi:10.1002/hep.27406

74.Wang, H., and Li,W. (2021). Recent Update on Comprehensive Therapy for Advanced HepatocellularCarcinoma. World J. Gastrointest. Oncol. 13 (8), 845–855.doi:10.4251/wjgo.v13.i8.845

75.Wang, J. H., Zeng,Z., Sun, J., Chen, Y., and Gao, X. (2021). A Novel SmallMolecule AntagonistEnhances the Sensitivity of Osteosarcoma to Cabozantinib In Vitro and In Vivoby Targeting DNMT-1 Correlated with

Disease Severity inHuman Patients. Pharmacol. Res. 173, 105869. doi:10.1016/j. phrs.2021.105869

76.Wang, Y., Li, Y.,Zai, W., Hu, K., Zhu, Y., Deng, Q., et al. (2022). HBV Covalently ClosedCircular DNA Minichromosomes in Distinct Epigenetic Transcriptional StatesDiffer in Their Vulnerability to Damage. Hepatology

75 (5), 1275–1288.doi:10.1002/hep.32245

77.Wang, Y., Ning,Y., Yuan, C., Cui, B., Liu, G., and Zhang, Z. (2021). The Protective Mechanismof a Debranched Corn Starch/konjac Glucomannan Composite against Dyslipidemiaand Gut Microbiota in High-Fat-Diet Induced Type 2

Diabetes. Food Funct.12 (19), 9273–9285.doi:10.1039/d1fo01233a

78.Wesley, S. F.,Haggiagi, A., Thakur, K. T., and De Jager, P. L. (2021). NeurologicalImmunotoxicity from Cancer Treatment. Int. J. Mol. Sci. 22 (13), 6716. doi:10.3390/ijms22136716

79.Wiese, E. K.,Hitosugi, S., Loa, S. T., Sreedhar, A., Andres-Beck, L. G., Kurmi, K., et al.(2021). Enzymatic Activation of Pyruvate Kinase Increases Cytosolic

Oxaloacetate toInhibit the Warburg Effect. Nat. Metab. 3 (7), 954–968.doi:10.1038/s42255-021-00424-5

80.Wu, L., Yang, W.,Zhang, Y., Du, X., Jin, N., Chen, W., et al. (2021). Elevated Serum Uric AcidIs Associated with Poor Survival in Advanced HCC Patients and FebuxostatImproves Prognosis in HCC Rats. Front.Pharmacol. 12, 778890.doi:10.3389/fphar.2021.778890

81.Xie, H., Tian, S.,Yu, H., Yang, X., Liu, J., Wang, H., et al. (2018). A New Apatinib MicrocrystalFormulation Enhances the Effect of Radiofrequency Ablation

Treatment onHepatocellular Carcinoma. Onco Targets Ther. 11, 3257–3265. doi:10.2147/OTT.S165000

82.Xie, H., Yu, H.,Tian, S., Yang, X., Wang, X., Yang, Z., et al. (2017). What Is the BestCombination Treatment with TransarterialChemoembolization of UnresectableHepatocellular Carcinoma? a Systematic Review and Network

Meta-Analysis.Oncotarget 8 (59), 100508–100523. doi:10.18632/oncotarget. 20119

83.Xu, J., Shen, J.,Gu, S., Zhang, Y., Wu, L., Wu, J., et al. (2021). Camrelizumab in Combinationwith Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): ANonrandomized, Open-Label, Phase II Trial. Clin.

Cancer Res. 27 (4),1003–1011.doi:10.1158/1078-0432.CCR-20-2571

84.Xu, M., Zhao, M.,Yang, R., Zhang, Z., Li, Y., and Wang, J. (2013). Effect of Dietary Nucleotideson Immune Function in Balb/C Mice. Int. Immunopharmacol. 17(1), 50–56.doi:10.1016/j.intimp.2013.04.032

85.Yan, Y., Zheng,L., Du, Q., and Geller, D. A. (2021). Interferon-γ/IRF-1 PathwayRegulatory Mechanisms of PD-L1 Expression and Relevance for Immune CheckpointBlockade in Hepatocellular Carcinoma (HCC). Oncotarget 12

(23), 2316–2317.doi:10.18632/oncotarget.27995

86.Yan, Y., Zheng,L., Du, Q., Yan, B., and Geller, D. A. (2020). Interferon Regulatory Factor 1(IRF-1) and IRF-2 Regulate PD-L1 Expression in Hepatocellular

Carcinoma (HCC)Cells. Cancer Immunol. Immunother. 69 (9), 1891–1903.doi:10.1007/s00262-020-02586-9

87.Yang, C., Xu, C.,Li, X., Zhang, Y., Zhang, S., Zhang, T., et al. (2021). Could Camrelizumab PlusChemotherapy Improve Clinical Outcomes in Advanced Malignancy? A SystematicReview and Network Meta-Analysis. Front. Oncol.

11, 700165.doi:10.3389/fonc.2021.700165

88.Yang, H., Zhang,M.-Z. -h., Sun, H.-w., Chai, Y.-t., Li, X., Jiang, Q., et al. (2021). A NovelMicrocrystalline BAY-876 Formulation Achieves Long-Acting Antitumor

Activity AgainstAerobic Glycolysis and Proliferation of Hepatocellular Carcinoma. Front. Oncol.11, 783194. doi:10.3389/fonc.2021.783194

89.Yau, T., Kang, Y.K., Kim, T. Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., et al. (2020). Effificacyand Safety of Nivolumab Plus Ipilimumab in Patients with

AdvancedHepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040Randomized Clinical Trial. JAMA Oncol. 6 (11),e204564.doi:10.1001/jamaoncol.2020.4564

90.Yi, C., Chen, L.,Lin, Z., Liu, L., Shao, W., Zhang, R., et al. (2021). Lenvatinib Targets FGFReceptor 4 to Enhance Antitumor Immune Response of AntiProgrammed Cell Death-1in HCC. Hepatology 74 (5), 2544–2560. doi:10.1002/

hep.31921

91.Yi, X., Qi, M.,Huang, M., Zhou, S., and Xiong, J. (2022). Honokiol Inhibits HIF-1α- MediatedGlycolysis to Halt Breast Cancer Growth. Front. Pharmacol. 13, 796763.doi:10.3389/fphar.2022.796763

92.Yin, F., Feng, F.,Wang, L., Wang, X., Li, Z., and Cao, Y. (2019). SREBP-1 Inhibitor BetulinEnhances the Antitumor Effect of Sorafenib on Hepatocellular

Carcinoma viaRestricting Cellular Glycolytic Activity. Cell. Death Dis. 10 (9),672.doi:10.1038/s41419-019-1884-7

93.Younossi, Z.,Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., et al.(2019). Global Perspectives on Nonalcoholic Fatty Liver Disease and

NonalcoholicSteatohepatitis. Hepatology 69 (6), 2672–2682. doi:10.1002/hep. 30251

94.Zhang, S., Wang,F., and Zhang, Z. (2017). Current Advances in the Elimination of Hepatitis B inChina by 2030. Front. Med. 11 (4), 490–501. doi:10.1007/s11684-

017-0598-4

95.Zhang, Y., Gao,J., Bao, Y., Liu, Y., Tong, Y., Jin, S., et al. (2022). Diagnostic Accuracy andPrognostic Signifificance of Osteopontin in Liver Cirrhosis and

HepatocellularCarcinoma: a Meta-Analysis. Biomarkers 27 (1), 13–21.doi:10.1080/1354750X.2021.2008009

96.Zhang, Y., Hui,F., Yang, Y., Chu, H., Qin, X., Zhao, M., et al. (2017). Can Kushen InjectionCombined with TACE Improve Therapeutic Effificacy and Safety in Patients withAdvanced HCC? a Systematic Review and Network Meta-Analysis. Oncotarget 8 (63),107258–107272. doi:10.18632/oncotarget.20921

97.Zhou, W., Gao, Y.,Tong, Y., Wu, Q., Zhou, Y., and Li, Y. (2021). Anlotinib Enhances the AntitumorActivity of Radiofrequency Ablation on Lung Squamous Cell Carcinoma. Pharmacol.Res. 164, 105392. doi:10.1016/j.phrs. 2020.105392

98.Zhu, Y. J., Zheng,B., Wang, H. Y., and Chen, L. (2017). New Knowledge of the Mechanisms ofSorafenib Resistance in Liver Cancer. Acta Pharmacol. Sin. 38 (5), 614–622.doi:10.1038/aps.2017.5

99.Zongyi, Y., andXiaowu, L. (2020). Immunotherapy for Hepatocellular Carcinoma. Cancer Lett.470, 8–17. doi:10.1016/j.canlet.2019.12.002

100.Zou, X. Z., Hao,J. F., and Zhou, X. H. (2021). Inhibition of SREBP-1 Activation by a NovelSmall-Molecule Inhibitor Enhances the Sensitivity of Hepatocellular

Carcinoma Tissue toRadiofrequency Ablation. Front. Oncol. 11, 796152. doi:10.3389/fonc.2021.796152